Netherlands· NL-affa977c8fbb
Lactulose Fresenius 670 mg/ml, stroop
A lactulose product containing lactulose, vloeibaar, registered in Netherlands by Fresenius Kabi Nederland B.V.. The same ATC class is registered in 16 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Lactulose is registered in 16 of 19 countries.
Countries holding a registration under ATC A06AD11 (lactulose), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Lactulose · ATC A06AD11
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- LACTULOSE, VLOEIBAAR
- Manufacturer
- Fresenius Kabi Nederland B.V.
- Country
- Netherlands (NL)
- ATC code
- A06AD11
- ATC class
- Lactulose
- Defined daily dose
- 12.5 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id107559
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
657 interactions on record for lactulose.
Graded by severity as the source publishes them — 263 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lactulose · interactions on record
657 records
- 263 moderate
- 18 minor
- 376 info
Most severe, free to view
- CisaprideA03FA02moderate
- OndansetronA04AA01moderate
- GranisetronA04AA02moderate
- DolasetronA04AA04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A06AD11
Lactulose, as other registers publish it.
- NetherlandsAlbert Heijn Laxeerdrank Lactulose 667 mg/ml, stroopHealthypharm B.V.
- GermanyBifiteralCooper Consumer Health Deutschland Gmbh
- United KingdomBifiteral 10g oral powder sachetsImported (Germany)
- BelgiumBifiteral 66.7 g/100 mlCooper Consumer Health
- GermanyBifiteral Mit PflaumenaromaCooper Consumer Health B.V.
- GermanyBifiteral Mit PflaumenaromaViatris Healthcare Gmbh
- IrelandBrillphalac 3.335 g/5 ml oral solutionBrillpharma (Ireland) Limited
- United StatesConstuloseActavis Pharma, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e9ce6ab6-ef38-4e8b-890b-264b1f97b005 GET /v1/drugs/e9ce6ab6-ef38-4e8b-890b-264b1f97b005?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stroop",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h107559_smpc.pdf",
"strength": null,
"atc_label": "Lactulose",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg107559",
"excipients": [
"GEEN HULPSTOFFEN"
],
"substances": [
"LACTULOSE, VLOEIBAAR"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h107559.pdf",
"authorised_at": "2010/10/28",
"procedure_number": "AT/H/0383/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "107559",
"additional_monitoring": "N"
}See everything about lactulose.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.